81 completed, 10 not yet recruiting, 10 unknown, 9 terminated. 28 Phase 2, 24 Not applicable, 24 Phase 4, 22 Phase 3, 18 Phase 1.
Follow Malaria, Vivax: new trials by email Literature Review of Malaria, Vivax trials Research Report on Malaria, Vivax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine | Phase 1 | Not yet recruiting | Guangzhou Patronus Biotech Co., Ltd. | 72 | 2026-10-01 | 2026-10-22 |
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| Tafenoquine and ACTs (TADORE- Plus) Tafenoquine plus DHA-Piperaquine, Tafenoquine plus Artesunate-pyronaridine - Vivax Malaria | Phase 4 | Not yet recruiting | Menzies School of Health Research | 507 | 2026-06-01 | 2026-03-18 |
| Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax Tafenoquine (TQ), Chloroquine (CQ), Dihydroartemisinin-piperaquine (DHA-PPQ) - Uncomplicated P. Vivax Mono-infection | Not applicable | Not yet recruiting | Walter Reed Army Institute of Research (WRAIR) | 300 | 2026-05-01 | 2026-04-16 |
| Postpartum 8-aminoquinoline Breast Milk Study Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers | Phase 2 / Phase 3 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-03-18 |
| Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine - Uncomplicated Malaria | Phase 4 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-02-12 |
| Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia PvCS/Montanide ISA-51 VG Vaccine, Placebo - Montanide ISA-51 VG Adjuvant Alone - Plasmodium Vivax Malaria, Plasmodium Vivax Infection | Phase 2 | Not yet recruiting | Malaria Vaccine and Drug Development Center | 72 | 2026-01-19 | 2026-01-28 |
| Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat - Pharmacokinetics of Tafenoquine | Phase 4 | Recruiting | Curtin University | 30 | 2025-10-20 | 2026-03-18 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax." Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory, Placebo - Malaria Vivax | Phase 1 | Not yet recruiting | Federal University of Minas Gerais | 48 | 2025-09-01 | 2025-09-15 |
| Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar PvSeroTAT, Control - Malaria Vivax, Malaria Falciparum | Phase 3 | Recruiting | London School of Hygiene and Tropical Medicine | 19200 | 2025-05-12 | 2026-09-18 |
| Vivax Elimination With Tafenoquine (VET) Study Tafenoquine - Malaria, Malaria, Vivax | Phase 4 | Completed | Shoklo Malaria Research Unit | 1242 | 2025-02-19 | 2026-01-06 |
| Efficacy of Chloroquine-Primaquine Treatment for Uncomplicated Plasmodium Vivax Malaria CQ-PQ - Malaria Vivax | Not applicable | Completed | Jimma University | 192 | 2024-12-01 | 2026-08-10 |
| An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older Tafenoquine, Primaquine, Chloroquine - Malaria, Vivax | Phase 3 | Recruiting | GlaxoSmithKline | 324 | 2024-11-13 | 2026-10-01 |
| FocaL Mass Drug Administration for Vivax Malaria Elimination Focal Mass Drug Administration (fMDA) - Plasmodium Vivax Malaria, Malaria | Phase 3 | Recruiting | University of California, San Francisco | 7530 | 2024-10-14 | 2026-06-09 |
| Southeast Asia Dose Optimization of Tafenoquine Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg - Plasmodium Vivax Malaria | Phase 4 | Recruiting | University of Oxford | 820 | 2024-07-22 | 2026-10-09 |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer Plasmodium immunotherapy - Advanced Ovarian Cancer | Phase 2 / Phase 3 | Not yet recruiting | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | 30 | 2024-07-20 | 2024-07-22 |
| Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). - Vivax Malaria, G6PD Deficiency | Phase 4 | Recruiting | Menzies School of Health Research | 100 | 2024-05-17 | 2026-03-12 |
| A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria Tafenoquine, Primaquine - Vivax Malaria | Phase 3 | Recruiting | Menzies School of Health Research | 1090 | 2024-05-10 | 2025-07-18 |
| Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru Tafenoquine (TQ) - Malaria, Vivax | Completed | Medicines for Malaria Venture | 187 | 2023-08-28 | 2026-03-20 |
Showing 20 of 123. Sign in to see all of them.
Malaria (50) · Malaria, Falciparum (30) · Recurrence (12) · Glucosephosphate Dehydrogenase Deficiency (8) · Anemia (2) · Fever (2) · Breast Feeding (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Diseases (1) · Chills (1) · Communicable Diseases (1) · Heart Diseases (1) · Hemolysis (1) · Infections (1)
Mosquito-Borne Diseases (123) · Vector Borne Diseases (123) · Infections (122) · Parasitic Diseases (122) · Protozoan Infections (122) · Malaria (73) · Pathological Conditions, Signs and Symptoms (15) · Disease Attributes (14) · Pathologic Processes (14) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Anemia (8) · Anemia, Hemolytic (8) · Anemia, Hemolytic, Congenital (8) · Carbohydrate Metabolism, Inborn Errors (8)
Primaquine (45) · Chloroquine (37) · tafenoquine (26) · Artemether, Lumefantrine Drug Combination (8) · artenimol (7) · piperaquine (6) · Artesunate (5) · fanasil, pyrimethamine drug combination (4) · Amodiaquine (3) · chloroquine diphosphate (3) · Artemether (2) · Case Management (2) · Lumefantrine (2) · Matrix-M (2) · Pyrimethamine (2)
University of Oxford (23) · Menzies School of Health Research (11) · GlaxoSmithKline (9) · London School of Hygiene and Tropical Medicine (5) · Malaria Vaccine and Drug Development Center (5) · Medicines for Malaria Venture (5) · Centers for Disease Control and Prevention (4) · Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (4) · University of California, San Francisco (4) · Armed Forces Research Institute of Medical Sciences, Thailand (3) · Curtin University (3) · U.S. Army Medical Research and Development Command (3) · Walter Reed Army Institute of Research (WRAIR) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Papua New Guinea Institute of Medical Research (2)
Thailand (21) · Brazil (14) · Indonesia (14) · Ethiopia (13) · Papua New Guinea (10) · Cambodia (8) · Colombia (8) · Peru (8) · United States (8) · Vietnam (8) · United Kingdom (6) · Afghanistan (4) · Laos (4) · France (3) · Pakistan (3)
Francois Nosten, MD (4) · Adam Bennett, MA, PhD (2) · Angela M Minassian, MBBS MA DPhil MRCP FRCPath (2) · Brioni R Moore, PhD (2) · Cindy Chu, MD, PhD (2) · Emiliana Tjitra (2) · Ivo Mueller, PhD (2) · Mark Rowland, PhD (2) · Rose McGready, MD (2) · Socrates Herrera, MD (2) · Adrian V S Hill, MD (1)
PMID 35664997, PMID 36534705, PMID 28193647, PMID 34609964, PMID 40670924, PMID 11716100, PMID 11741694, PMID 11816444, PMID 12171615, PMID 12476490, PMID 13356045, PMID 14579464, PMID 14582335, PMID 15155976, PMID 15330070, PMID 1688828, PMID 17336652, PMID 17519409, PMID 17707447, PMID 18612426, PMID 18682739, PMID 19707564, PMID 20409302, PMID 2094597, PMID 21292874, PMID 21798054, PMID 21931708, PMID 22427705, PMID 22443344, PMID 22531245, PMID 22759078, PMID 23212366, PMID 23217037, PMID 23717423, PMID 23718705, PMID 23926329, PMID 24088113, PMID 24360369, PMID 24687509, PMID 24963662, PMID 25591391, PMID 25877962, PMID 26006260, PMID 26248362, PMID 26286026, PMID 26448141, PMID 26500351, PMID 26505753, PMID 26518132, PMID 26643116
R01AI103228 (1), U01AI157962 (1), U01AI195203 (1)